Skip to content
TrialScanner

NCT05664217

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Phase 2/Phase 3TerminatedNKTRLead

Registry record

Lead sponsor
Nektar Therapeutics
Conditions
Non-Hodgkin Lymphoma; Relapsed/Refractory Diffuse Large B-cell Lymphoma
Primary completion
May 22, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05664217 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.